Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis

Archivio Italiano di Urologia e Andrologia

Volumn 87, Issue 2, 2015, Pages 121-129

  Perletti, Gianpaolo ^a,b   Monti, Elena ^a   Marras, Emanuela ^a   Cleves, Anne ^c   Magri, Vittorio ^d   Trinchieri, Alberto ^e   Rennie, Paul S ^f  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b GHENT UNIVERSITY   (Belgium)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d PARKINSON INSTITUTE   (Italy)

^e A MANZONI HOSPITAL   (Italy)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Castration resistant prostate cancer; Chemotherapy; Hormone therapy

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; IPILIMUMAB; MINERALOCORTICOID; MITOXANTRONE; ORTERONEL; PLACEBO; PREDNISONE; 17-(3-PYRIDYL)-5,16-ANDROSTADIEN-3BETA-ACETATE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; MONOCLONAL ANTIBODY; NAPHTHALENE DERIVATIVE; PHENYLTHIOHYDANTOIN; TAXOID;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HAZARD RATIO; HUMAN; HYPERTENSION; HYPOKALEMIA; MALE; META ANALYSIS; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEROID RELEASE; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; DISEASE COURSE; EVIDENCE BASED MEDICINE; MORTALITY; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK FACTOR; SECONDARY; SURVIVAL; TIME; TREATMENT OUTCOME;

ANDROSTENES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HUMANS; IMIDAZOLES; MALE; NAPHTHALENES; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL ANALYSIS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84947345306     PISSN: 11243562     EISSN: 22824197     Source Type: Journal    
DOI: 10.4081/aiua.2015.2.121     Document Type: Review

References (26)

1. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1, 589 patients. Hum Pathol. 2000; 31:578.
2. Droz J P, Flechon A, Terret C. Prostate cancer: management of advanced disease. Ann Oncol. 2002; 13 Suppl4: 89.
3. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011; 59:572.
4. Tannock I F, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med. 2004; 351:1502.
5. Mathew P, Dipaola R. Taxane refractory prostate cancer. J Urol. 2007; 178:S36.
6. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151:264.
7. Higgins J P, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928.
8. Niimi M, Yamamoto S, Fukuda H, et al. The Influence of handling censored data on estimating progression-free survival in cancer clinical trials (JCOG9913-A). Japan J Clin Oncol. 2002; 32:19.
9. Guyatt GH, Oxman AD, Kunz R, et al. What is "quality of evidence" and why is it important to clinicians? BMJ 2008; 336:995.
10. Scher HI, Fizazi K, Saad F, et al. Increased survival with enza-lutamide in prostate cancer after chemotherapy. New Engl J Med. 2012; 367:1187.
11. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet oncol. 2014; 15:700.
12. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. New Engl J Med. 2011; 364:1995.
13. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012; 13:983.
14. Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012; 13:1210.
15. Sternberg CN, Molina A, North S, et al. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Ann Oncol. 2013; 24:1017.
16. Fizazi K, Jones R, Oudard S, et al. Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5. J Clin Oncol. 2015; pii: JCO.2014.56.5119 [Epub ahead of print].
17. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147.
18. Oudard S. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Fut Oncol. 2011; 7:497.
19. Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol. 2013; 24:2402.
20. Cookson MS, Roth BJ, Dahm P, et al. Castration-Resistant Prostate Cancer: AUA Guideline. J Urol. 2013; 190:429.
21. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375:1437.
22. Sartor O, Pal SK. Abiraterone and its place in the treatment of metastatic CRPC. Nature Rev Clin Oncol. 2013; 10:6.
23. Aggarwal R, Halabi S, Kelly WK, et al. The effect of prior andro-gen synthesis inhibition on outcomes of subsequent therapy with doc-etaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401). Cancer 2013; 119:3636.
24. Noonan KL, North S, Bitting RL, et al. Clinical activity of abi-raterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013; 24:1802.
25. Loriot Y, Bianchini D, Ileana E, et al. Antitumour activity of abi-raterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol. 2013; 24:1807.
26. Bianchini D, Lorente D, Rodriguez-Vida A, et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with doc-etaxel and abiraterone. Eur J Cancer 2014; 50:78.